The 9MMNon-Cystic Fibrosis Bronchiectasis Drug Treatment Market is expected to offer an $ opportunity of USD 3,530.8 Million over the analysis period. Market was estimated USD 3,223.5 Million during 2023 and expected to grow at a significant CAGR 17.4% over the projected period. And by the end of 2033, the market is expected to touch USD 6,754.3 Million.
Pipeline drugs expected to provide an opportunity of more than USD 6,572.7 Million during the forecast year.
Disease Overview: A chronic inflammatory lung disease known as non-cystic fibrosis bronchiectasis (NCFB) is linked to respiratory infections as well as persistent coughing and sputum production. Pneumonia, cilia abnormalities, and immunological deficits are some of the causes. The elderly are more commonly affected. Patients with non-cystic fibrosis bronchiectasis (NCFB) generally have worse quality of life and higher morbidity. High-resolution computed tomography (HR-CT) scanning is presently used to diagnose NCFB. The primary diagnostic characteristics encompasses a bronchus's internal diameter being greater than the pulmonary artery next to it, the bronchi's inability to taper, and the presence of bronchi in the outer 1-2 cm of the lung fields. Since HR-CT is so widely accessible, it has been determined that bronchiectasis is still a common and significant source of respiratory illnesses.Read more….
Report has deeply investigated patient’s presentation and tailored treatment
Report has Covered Granular-level Analysis in Each Mapped Market
Non-Cystic Fibrosis Bronchiectasis Disease Burden Analysis: (Result shown here is reflecting from meta-analysis, and CSP Analytics Solutions Analysis)
This section explored the epidemiology associated with Non-Cystic Fibrosis Bronchiectasis across regions
Experts indicated prevalence increased significantly across regions, but gaps in estimates still persist.
Our research report has provided crystal clear view of prevalent pool across regions. Since epidemiology estimation accompanied with lot of complexity, our report has streamlined the estimation process for enhancing market understanding.
Report has also highlighted, impact of improvements in diagnosis, on diagnosis rate (%).
Non-Cystic Fibrosis Bronchiectasis Cases: 9MM
Non-Cystic Fibrosis Bronchiectasis accounts for XX million cases in 9MM
Non-Cystic Fibrosis Bronchiectasis accounts for XX million cases in United States
Non-Cystic Fibrosis Bronchiectasis accounts for XX million cases in China
Non-Cystic Fibrosis Bronchiectasis accounts for XX million cases in India
Non-Cystic Fibrosis Bronchiectasis accounts for XX million cases in Japan
Non-Cystic Fibrosis Bronchiectasis accountsfor XX million cases in Rest of World
Immediate antibiotic treatment is suggested for patients presenting with rising cough, sputum volume and purulence. There’re multiple unanswered questions, which includes mode, choice and duration of antibiotic, monotherapy or dual agents and how best to assess and monitor response to treatment.
This report section deals with the treatment strategies adopted by healthcare professional while dealing across patients’ segments. Also provided gaps in current treatment and upcoming treatment options.
The treatment of Non-Cystic Fibrosis Bronchiectasis typically involves the use of Antibiotics, Bronchodilators, Mucolytics, Expectorants, Corticosteroids and Anti-inflammatory Agents, and Emerging Therapies.
Treatment of Non-Cystic Fibrosis Bronchiectasis’s requires holistic framework to address diverse set of patients. Collaboration among various specialties is imperative to devise tailoring treatment plan. Efforts to encourage diagnosis rate and advocacy at patient and physician level is crucial to provide better therapeutic options.
Report section covers detailed around various types of available treatments
Antibiotics
Bronchodilators
Mucolytics
Expectorants
Corticosteroids and Anti-inflammatory Agents
Emerging Therapies
Also covers patient segment targeted by each therapy type: This section address concerns regarding unaddressed patient pool
Several companies and institutions collaborating to bring out the appropriate treatment solutions
Our report analysis revealed that, there are tremendous opportunities exits in the market in order to close the current market gaps
Recent clinical guidelines enable the streamlining the treatment approaches
Report has examined the how many and what type of cases refer to which type of therapy based on experts’ opinion analysis.
Untreated Prevalent Pool of Non-Cystic Fibrosis Bronchiectasis
Huge medical unmet need
Advancements in diagnosis tools
Advancements in Treatment Options
Proliferation of novel treatment options
Advent of emerging therapy for developing tailoring treatment
Emergence of Targeted Therapies
Market Challenges: Explored in the report
Limited Treatment Options
High Treatment Costs
Clinical Trial Enrollments
Access to Care and Treatment
Research and development gaps
Misdiagnosis and Underdiagnosis
Lack of adequate treatment compliance and adherence
Non-Cystic Fibrosis BronchiectasisMapped Geography: Nine Major Markets (9MM)
Report has fragmented the total market into five regions such as:
United States
5-Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
China
Japan
India
RoW (Rest of World)
Each mapped region has been examined at granular level based on below parameters:
United States Non-Cystic Fibrosis Bronchiectasis Drug Treatment Market: The Non-Cystic Fibrosis Bronchiectasis (NCFB) market in the United States is experiencing significant growth, accompanied by rising disease prevalence, advancements in diagnostics, and the development of novel therapies. Prominent players involved in the market such as Insmed Incorporated, Chiesi Farmaceutici, Renovion. Armata Pharmaceuticals, and CSL Behring. United States NCFB market is expected to witness the substantial growth, combined with rising disease prevalence, advancements in diagnostics, and a robust pipeline of emerging therapies.
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Market Unmet Need Analysis
5-Europe Non-Cystic Fibrosis Bronchiectasis Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
By Country
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
China Non-Cystic Fibrosis Bronchiectasis Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
India Non-Cystic Fibrosis Bronchiectasis Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Japan Non-Cystic Fibrosis Bronchiectasis Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Rest of the World Non-Cystic Fibrosis Bronchiectasis Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Non-Cystic Fibrosis Bronchiectasis Competitive Landscape (Existing and Pipeline Players):
Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.
Company Profiles:
Verona Pharma plc
AstraZeneca
Insmed Incorporated
Haisco Pharmaceutical Group Co., Ltd.
Chiesi Farmaceutici S.p.A.
Renovion, Inc.
SolAeroMed Inc.
Zambon SpA
Boehringer Ingelheim
Aradigm Corporation
Alaxia SAS
Armata Pharmaceuticals, Inc.
ResBiotic Nutrition, Inc.
Genentech, Inc.
Others
Reason to buy this report:
Fostering Understanding on Non-Cystic Fibrosis Bronchiectasis Treatment Market
In Order to Understand the Market Potential
Opportunity Analysis (exist in the market for players)
